Erwin Boos covers Schroder Adveq’s investment activity in the life science sector. Prior to joining Schroder Adveq in 2006, Erwin worked as a Consultant for Accenture in the firm’s life science practice. He also spent five years doing research in the field of gene therapy working for start-ups and public organizations in France and in the UK.
Erwin holds a PharmD from Louis Pasteur University in Strasbourg, France, an MBA from ESSEC Business School and a Diplom-Kaufmann degree from Mannheim University, Germany.
He currently serves as board observer at Alentis Therapeutics, Memo Therapeutics, ImmunOs and iOnctura. Erwin also led the investments on Amal Therapeutics (acquired by Boehringer Ingelheim), Araris Biotech, Goldfinch Bio, Pliant Therapeutics, Rapt Therapeutics (NASDAQ: RAPT) and Revolution Medicines (NASDAQ: RVMD).